[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651815":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":38,"centralContacts":42,"locations":48,"responsibleParty":192,"collaborators":33,"id":194,"slug":195,"hasResults":196,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":33,"eligibilityCriteria":200,"healthyVolunteers":196,"sex":201,"minAge":202,"maxAge":203,"enrollmentInfo":204,"targetDuration":33,"studyType":207,"phases":208,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":219,"whyStopped":33,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":229},{"fullName":5,"class":6},"Spyre Therapeutics, Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"SPY072 + bimekizumab","EXPERIMENTAL","Participants receive SPY072 + bimekizumab",[13,14],"Drug: SPY072","Drug: bimekizumab",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo + bimekizumab","PLACEBO_COMPARATOR","Participants receive matching placebo for SPY072 + bimekizumab",[20,14],"Drug: Placebo",[22,29,34],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","SPY072","Solution for SC injection",[9],[28],"SPY002-072",{"type":23,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Placebo","Matching placebo for SC injection",[16],null,{"type":23,"name":35,"description":36,"armGroupLabels":37,"otherNames":33},"bimekizumab","Advanced standard of care",[16,9],[39],{"name":40,"affiliation":5,"role":41},"Joshua Friedman, MD, PhD","STUDY_DIRECTOR",[43],{"name":44,"role":45,"phone":46,"phoneExt":33,"email":47},"SKYLIGHT Trial Center","CONTACT","1-702-602-7976","info@SKYLIGHT-trial.com",[49,64,76,88,100,111,123,134,145,157,169,180],{"facility":50,"status":33,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Site 111","Irvine","California","92614","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-117.82311,33.66946,{"lat":60,"lon":59},[63],{"name":44,"role":45,"phone":33,"phoneExt":33,"email":33},{"facility":65,"status":33,"city":66,"state":67,"zip":68,"country":54,"countryCode":55,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Site 101","Indianapolis","Indiana","46250",{"type":57,"coordinates":70},[71,72],-86.15804,39.76838,{"lat":72,"lon":71},[75],{"name":44,"role":45,"phone":33,"phoneExt":33,"email":33},{"facility":77,"status":33,"city":78,"state":79,"zip":80,"country":54,"countryCode":55,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Site 100","Bowling Green","Kentucky","42104",{"type":57,"coordinates":82},[83,84],-86.4436,36.99032,{"lat":84,"lon":83},[87],{"name":44,"role":45,"phone":33,"phoneExt":33,"email":33},{"facility":89,"status":33,"city":90,"state":91,"zip":92,"country":54,"countryCode":55,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Site 108","Baton Rouge","Louisiana","70809",{"type":57,"coordinates":94},[95,96],-91.18747,30.44332,{"lat":96,"lon":95},[99],{"name":44,"role":45,"phone":33,"phoneExt":33,"email":33},{"facility":101,"status":33,"city":102,"state":91,"zip":103,"country":54,"countryCode":55,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Site 110","New Orleans","70115",{"type":57,"coordinates":105},[106,107],-90.07507,29.95465,{"lat":107,"lon":106},[110],{"name":44,"role":45,"phone":33,"phoneExt":33,"email":33},{"facility":112,"status":33,"city":113,"state":114,"zip":115,"country":54,"countryCode":55,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Site 103","Boston","Massachusetts","02115",{"type":57,"coordinates":117},[118,119],-71.05977,42.35843,{"lat":119,"lon":118},[122],{"name":44,"role":45,"phone":33,"phoneExt":33,"email":33},{"facility":124,"status":33,"city":125,"state":125,"zip":126,"country":54,"countryCode":55,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Site 102","New York","10023",{"type":57,"coordinates":128},[129,130],-74.00597,40.71427,{"lat":130,"lon":129},[133],{"name":44,"role":45,"phone":33,"phoneExt":33,"email":33},{"facility":135,"status":33,"city":136,"state":125,"zip":137,"country":54,"countryCode":55,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Site 104","The Bronx","10455",{"type":57,"coordinates":139},[140,141],-73.86641,40.84985,{"lat":141,"lon":140},[144],{"name":44,"role":45,"phone":33,"phoneExt":33,"email":33},{"facility":146,"status":33,"city":147,"state":148,"zip":149,"country":54,"countryCode":55,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Site 109","Mt. Pleasant","South Carolina","29464",{"type":57,"coordinates":151},[152,153],-79.86259,32.79407,{"lat":153,"lon":152},[156],{"name":44,"role":45,"phone":33,"phoneExt":33,"email":33},{"facility":158,"status":33,"city":159,"state":160,"zip":161,"country":54,"countryCode":55,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"Site 105","Dallas","Texas","75246",{"type":57,"coordinates":163},[164,165],-96.80667,32.78306,{"lat":165,"lon":164},[168],{"name":44,"role":45,"phone":33,"phoneExt":33,"email":33},{"facility":170,"status":33,"city":171,"state":160,"zip":172,"country":54,"countryCode":55,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"Site 107","Tyler","75703",{"type":57,"coordinates":174},[175,176],-95.30106,32.35126,{"lat":176,"lon":175},[179],{"name":44,"role":45,"phone":33,"phoneExt":33,"email":33},{"facility":181,"status":33,"city":182,"state":183,"zip":184,"country":54,"countryCode":55,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"Site 106","Mill Creek","Washington","98012",{"type":57,"coordinates":186},[187,188],-122.2043,47.8601,{"lat":188,"lon":187},[191],{"name":44,"role":45,"phone":33,"phoneExt":33,"email":33},{"type":193,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100651815","phase-2-a-study-of-spy072-in-adults-with-moderate-to-severe-hidradenitis-suppurativa-the-skylight-trial-100651815",false,"NCT07766005","A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial to Assess the Efficacy and Safety of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa Receiving Standard of Care Treatment","Inclusion Criteria:\n\n* Clinical diagnosis of Hidradenitis Suppurativa with symptoms for at least 6 months before screening.\n* Hidradenitis suppurativa lesions in at least 2 distinct anatomical areas, with at least 1 area meeting Hurley Stage II or III criteria at screening and Day 1.\n* Total abscess and\u002For inflammatory nodule count of at least 5 at screening and Day 1.\n* Documented inadequate response, intolerance, or contraindication to at least 1 systemic therapy for hidradenitis suppurativa.\n\nExclusion Criteria:\n\n* More than 20 draining tunnels at screening or Day 1.\n* Hidradenitis suppurativa lesion expected to require incision and drainage within 4 weeks before Day 1, or major hidradenitis suppurativa surgery within 12 weeks before Day 1.\n* Another inflammatory or skin condition that could interfere with assessment of hidradenitis suppurativa.","ALL","18 Years","75 Years",{"count":205,"type":206},150,"ESTIMATED","INTERVENTIONAL",[209],"PHASE2","This Phase 2 study will test whether the investigational medicine, SPY072, improves hidradenitis suppurativa (HS) in adults with moderate to severe disease receiving advanced standard of care treatment. About 150 participants will be assigned by chance to receive either SPY072 or placebo for 16 weeks. Participants will be followed after the treatment period to evaluate safety and how long treatment effects may last.",[212],"Hidradenitis Suppurativa (HS)",[214,215,216,217,218],"Hidradenitis suppurativa","Hidradenitis","Skin diseases","Sweat gland diseases","Skin and connective tissue diseases","NOT_YET_RECRUITING","2026-08-10",{"date":222,"type":223},"2026-08-14","ACTUAL",{"date":225,"type":206},"2026-09",{"date":227,"type":206},"2028-06",{"name":5,"class":6},12]